scholarly journals A meta-analysis evaluating the impact of high-intensity focused ultrasound (HIFU) on survival and pain relief of patients with locally advanced pancreatic cancer

HPB ◽  
2021 ◽  
Vol 23 ◽  
pp. S759-S760
Author(s):  
M. Fergadi ◽  
D. Magouliotis ◽  
M. Vlychou ◽  
C. Rountas ◽  
D. Symeonidis ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Pain Relief ◽  
High Intensity ◽  
Focused Ultrasound ◽  
Meta Analysis ◽  
Locally Advanced ◽  
Advanced Pancreatic Cancer ◽  
High Intensity Focused Ultrasound ◽  
Locally Advanced Pancreatic Cancer ◽  
The Impact

The value of dynamic contrast enhanced ultrasound (DCE-US) in monitoring treatment effect of high-intensity focused ultrasound (HIFU) in locally advanced pancreatic cancer (LAPC)

2020 ◽  
pp. 1-11
Author(s):  
Zuo Dan ◽  
Feng Yi ◽  
Zhang Qi ◽  
Qiu Yi-Jie ◽  
Tian Xiao-Fan ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
High Intensity ◽  
Focused Ultrasound ◽  
Locally Advanced ◽  
Advanced Pancreatic Cancer ◽  
High Intensity Focused Ultrasound ◽  
Contrast Enhanced Ultrasound ◽  
Hifu Treatment ◽  
Dynamic Contrast Enhanced ◽  
Contrast Enhanced

PURPOSE: To evaluate the feasibility of dynamic contrast enhanced ultrasound (DCE-US) in predicting treatment response of high-intensity focused ultrasound (HIFU) in patients with locally advanced pancreatic cancer (LAPC) lesions. PATIENTS AND METHODS: In this prospective study, 10 patients with pathologically confirmed LAPC lesions (7 men, 3 women; average age, 61.13±5.80 years) were prospectively enrolled. All patients received HIFU treatment with peak intensity at 12000 W/cm2. Contrast enhanced ultrasound (CEUS) was performed with an ACUSON Oxana 2 ultrasound equipment and a 6 C-1 transducer (1–6 Hz). A dose of 2.4 ml SonoVue was injected for each examination. Time intensity curves (TICs) were generated and quantitative analyses were performed by SonoLiver software. B mode ultrasound (BMUS) features, CEUS enhancement patterns, TICs, CEUS quantitative parameters and serum carcinoma antigen 19-9 (CA19-9) levels were compared before and 4 weeks after HIFU treatment. Statistical analyses were performed with SPSS Version 20.0 and GraphPad Prism 5. RESULTS: While comparing before and after HIFU, no significant difference was obtained on mean size of lesion, BMUS or CEUS features. After HIFU treatment, TICs showed decreased and delayed enhancement. Among all CEUS quantitative parameters, significant decrease could be found in maximum intensity (MI) (60.66±23.95% vs 41.31±26.74%) and mean transit time (mTT) (76.66±47.61 s vs 38.42±28.35 s). CA19-9 level decreased significantly after HIFU (2747.92±4237.41 U/ml vs 715.08±1773.90 U/ml) (P = 0.05). CONCLUSION: DCE-US combining with quantitative analysis might be a useful imaging method for early treatment response evaluation of HIFU in LAPC lesions.

scholarly journals Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer—A Systematic Review and Meta-Analysis

Cancers ◽  
2021 ◽  
Vol 13 (17) ◽  
pp. 4326
Author(s):  
Marko Damm ◽  
Ljupcho Efremov ◽  
Benedikt Birnbach ◽  
Gretel Terrero ◽  
Jörg Kleeff ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Meta Analysis ◽  
Objective Response ◽  
Locally Advanced ◽  
Advanced Pancreatic Cancer ◽  
Locally Advanced Pancreatic Cancer ◽  
R0 Resection ◽  
Borderline Resectable ◽  
Intention To Treat ◽  
The Impact

Therapy with gemcitabine and nab-paclitaxel (GNP) is the most commonly used palliative chemotherapy, but its advantage in the neoadjuvant setting remains unclear. Accordingly, our aim is to evaluate the impact of first-line neoadjuvant therapy with GNP in patients with borderline resectable (BRPC) and locally advanced pancreatic cancer (LAPC). A systematic search for published studies until August 2020 was performed. The primary endpoint included resection and R0 resection rates in the intention-to-treat population. Secondary endpoints were response rate, survival and toxicity. Among 21 studies, 950 patients who received neoadjuvant GNP were evaluated. Treatment with GNP resulted in surgical resection and R0 resection rates as follows: 49% (95% CI 30–68%) and 36% (95% CI 17–58%) for BRPC and 16% (95% CI 7–26%) and 11% (95% CI 5–19%) for LAPC, respectively. The objective response rates and the median overall survival (mOS) ranged from 0 to 67% and 12 to 30 months, respectively. Neutropenia (range 5–77%) and neuropathy (range 0–22%) were the most commonly reported grade 3 to 4 adverse events. Neoadjuvant chemotherapy with GNP can be performed safely and with valuable effects in patients with BRPC and LAPC. The utility of GNP in comparison to FOLFIRINOX in the neoadjuvant setting requires further investigation in prospective randomized trials.

scholarly journals High-Intensity Focused Ultrasound Treatment for Advanced Pancreatic Cancer

2014 ◽  
Vol 2014 ◽  
pp. 1-11 ◽  
Author(s):  
Yufeng Zhou
Keyword(s):  
Pancreatic Cancer ◽  
High Intensity ◽  
Focused Ultrasound ◽  
Advanced Pancreatic Cancer ◽  
High Intensity Focused Ultrasound ◽  
Treatment Modalities ◽  
Karnofsky Performance Scale ◽  
Great Success ◽  
Hifu Treatment ◽  
Performance Scale

Pancreatic cancer is under high mortality but has few effective treatment modalities. High-intensity focused ultrasound (HIFU) is becoming an emerging approach of noninvasively ablating solid tumor in clinics. A variety of solid tumors have been tried on thousands of patients in the last fifteen years with great success. The principle, mechanism, and clinical outcome of HIFU were introduced first. All 3022 clinical cases of HIFU treatment for the advanced pancreatic cancer alone or in combination with chemotherapy or radiotherapy in 241 published papers were reviewed and summarized for its efficacy, pain relief, clinical benefit rate, survival, Karnofsky performance scale (KPS) score, changes in tumor size, occurrence of echogenicity, serum level, diagnostic assessment of outcome, and associated complications. Immune response induced by HIFU ablation may become an effective way of cancer treatment. Comments for a better outcome and current challenges of HIFU technology are also covered.

scholarly journals Non invasive palliation for advanced pancreatic cancer using high intensity focused ultrasound

2014 ◽  
Vol 2 (Suppl 1) ◽  
pp. A2
Author(s):  
Michele Rossi ◽  
Riccardo Naspetti ◽  
Ernesto Mazza ◽  
Paolo Boninsegni
Keyword(s):  
Pancreatic Cancer ◽  
High Intensity ◽  
Focused Ultrasound ◽  
Advanced Pancreatic Cancer ◽  
High Intensity Focused Ultrasound ◽  
Non Invasive
Sign in / Sign up

Export Citation Format

Share Document